FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206033984> ?p ?o ?g. }

• W3206033984 abstract "Objective: Evaluate dose adjustment of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate, LXB; Xywav™; previously designated as JZP-258) during titration in a double-blind, placebo-controlled, randomized withdrawal study. Background: Sodium oxybate (SXB; Xyrem®) is a standard of care for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy. LXB is an oxybate medication with 92% less sodium than SXB. Design/Methods: At study entry, participants were taking SXB only, SXB+other anticataplectics, anticataplectics other than SXB, or were cataplexy treatment–naive. LXB treatment began during a 12-week, open-label optimized treatment and titration period. Participants taking SXB only or SXB+other anticataplectics transitioned to LXB at the same gram-for-gram dose as SXB and adjusted to an efficacious and tolerable (optimized) dose during weeks 3–12. Participants taking other anticataplectics or who were anticataplectic-naive initiated LXB at 4.5 g/night and titrated to an optimized dose at ≤1.5 g/night/week (maximum total dose, 9 g/night). A 2-week stable-dose period (SDP) and 2-week, double-blind, randomized withdrawal period followed. Results: Most participants (91%) taking SXB at study entry had no dose adjustment or adjustments within 1 titration step (±1.5 g/night). The median (range) number of adjustments was 0.0 (0–8) in participants taking SXB at study entry and 3.0 (0–7) in participants not taking SXB at study entry. Total nightly stable LXB dose (median [range]) was higher in participants taking SXB at study entry (SXB-only, 7.5 g [4.5–9.0], n=41; SXB+other anticataplectics, 9.0 g [6.0–9.0], n=14) compared with those not taking SXB (other anticataplectics, 7.5 g [4.5–9.0], n=21; anticataplectic-naive, 7.0 g [3.0–9.0], n=58), with fewer dose adjustments made. Conclusions: Most participants taking SXB at study entry transitioned to LXB at the same dose or within 1 titration step. Participants not previously taking SXB achieved an individually optimized dose of LXB after a median of 3 adjustments. Disclosure: Dr. Foldvary-Schaefer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Richard K. Bogan, MD has nothing to disclose. Dr. Thorpy has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz. Lin Huang has received personal compensation for serving as an employee of Jazz pharmaceuticals. Dr. Skowronski has nothing to disclose. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda." @default.
• W3206033984 created "2021-10-25" @default.
• W3206033984 creator A5030863641 @default.
• W3206033984 creator A5038093846 @default.
• W3206033984 creator A5045293371 @default.
• W3206033984 creator A5068431212 @default.
• W3206033984 creator A5070041246 @default.
• W3206033984 creator A5084367532 @default.
• W3206033984 date "2021-04-13" @default.
• W3206033984 modified "2023-09-23" @default.
• W3206033984 title "Lower-Sodium Oxybate Dose Titration and Transition From Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy (2163)" @default.
• W3206033984 hasPublicationYear "2021" @default.
• W3206033984 type Work @default.
• W3206033984 sameAs 3206033984 @default.
• W3206033984 citedByCount "0" @default.
• W3206033984 crossrefType "journal-article" @default.
• W3206033984 hasAuthorship W3206033984A5030863641 @default.
• W3206033984 hasAuthorship W3206033984A5038093846 @default.
• W3206033984 hasAuthorship W3206033984A5045293371 @default.
• W3206033984 hasAuthorship W3206033984A5068431212 @default.
• W3206033984 hasAuthorship W3206033984A5070041246 @default.
• W3206033984 hasAuthorship W3206033984A5084367532 @default.
• W3206033984 hasConcept C118552586 @default.
• W3206033984 hasConcept C126322002 @default.
• W3206033984 hasConcept C142724271 @default.
• W3206033984 hasConcept C168563851 @default.
• W3206033984 hasConcept C204787440 @default.
• W3206033984 hasConcept C27081682 @default.
• W3206033984 hasConcept C2779494582 @default.
• W3206033984 hasConcept C2780163352 @default.
• W3206033984 hasConcept C2780714222 @default.
• W3206033984 hasConcept C42219234 @default.
• W3206033984 hasConcept C71924100 @default.
• W3206033984 hasConceptScore W3206033984C118552586 @default.
• W3206033984 hasConceptScore W3206033984C126322002 @default.
• W3206033984 hasConceptScore W3206033984C142724271 @default.
• W3206033984 hasConceptScore W3206033984C168563851 @default.
• W3206033984 hasConceptScore W3206033984C204787440 @default.
• W3206033984 hasConceptScore W3206033984C27081682 @default.
• W3206033984 hasConceptScore W3206033984C2779494582 @default.
• W3206033984 hasConceptScore W3206033984C2780163352 @default.
• W3206033984 hasConceptScore W3206033984C2780714222 @default.
• W3206033984 hasConceptScore W3206033984C42219234 @default.
• W3206033984 hasConceptScore W3206033984C71924100 @default.
• W3206033984 hasOpenAccess W3206033984 @default.
• W3206033984 hasRelatedWork W1555860353 @default.
• W3206033984 hasRelatedWork W2335934270 @default.
• W3206033984 hasRelatedWork W2535734852 @default.
• W3206033984 hasRelatedWork W2785671481 @default.
• W3206033984 hasRelatedWork W2805066472 @default.
• W3206033984 hasRelatedWork W2805395543 @default.
• W3206033984 hasRelatedWork W2806435685 @default.
• W3206033984 hasRelatedWork W2806687972 @default.
• W3206033984 hasRelatedWork W2808055426 @default.
• W3206033984 hasRelatedWork W2808356172 @default.
• W3206033984 hasRelatedWork W2809523820 @default.
• W3206033984 hasRelatedWork W2809684180 @default.
• W3206033984 hasRelatedWork W2883358571 @default.
• W3206033984 hasRelatedWork W2885430857 @default.
• W3206033984 hasRelatedWork W2898365980 @default.
• W3206033984 hasRelatedWork W2976572331 @default.
• W3206033984 hasRelatedWork W3091005207 @default.
• W3206033984 hasRelatedWork W3195116409 @default.
• W3206033984 hasRelatedWork W1745697471 @default.
• W3206033984 hasRelatedWork W2809596465 @default.
• W3206033984 hasVolume "96" @default.
• W3206033984 isParatext "false" @default.
• W3206033984 isRetracted "false" @default.
• W3206033984 magId "3206033984" @default.
• W3206033984 workType "article" @default.